June 6 (Reuters) - A former human resources officer at Eli Lilly & Co (LLY.N) sued the pharmaceutical company on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving its blockbuster diabetes drug.
The plaintiff, Amrit Mula, alleges violations of an employee protection law and seeks unspecified damages. The U.S. Department of Justice last year launched a criminal investigation into alleged manufacturing irregularities at a Lilly plant in New Jersey following a Reuters story that detailed some of Mula's allegations. read more
A Lilly spokeswoman did not immediately respond to questions about the lawsuit, or on the status of the Justice Department's investigation.
"Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority," the company said last year.
Reached for comment, Mula said she "made every effort to resolve this controversy and avoid litigation entirely, but unfortunately we were unable to do so."
The Justice Department did not immediately respond to a request for comment.
An employee at the New Jersey plant starting in 2004, Mula contends in the lawsuit that she repeatedly pressured site leaders starting in 2018 to remedy manufacturing violations involving several biologic drugs, including diabetes medicine Trulicity. read more
"Lilly executives responded by marginalizing, harassing and...
A nursing home run by the family of Kim Keon-hee lost the first trial in a lawsuit seeking to cancel the National Health Insurance Service's disposition to claw back about 1.4 billion won in long-...